Compare Mesoblast Limited (MESO) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sezzle Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Sezzle Inc trades at $175.98 (market cap $5.78B). The key difference: Sezzle Inc is far larger — about 2.7× Mesoblast Limited's market cap, and Sezzle Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SEZL | |
|---|---|---|
Market Cap | $2.17B | $5.78B |
Sector | Technology | Technology |
52-Week High | $20.96 | $188.55 |
52-Week Low | $12.88 | $50.97 |
Enterprise Value | $2.17B | $5.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Sezzle (SEZL) trades at $171.76, down 1.67% today but maintaining strong momentum with consistent earnings beats and bullish technical indicators. The stock shows robust fundamentals with 30.83% net income margin and 91.95% ROE, though valuations remain elevated at P/E 41.72. Recent news highlights product expansion and strong Q1 2026 results, with the company scheduled to report Q2 earnings on August 6, 2026.
Outlook remains positive given earnings momentum and analyst consensus, but high valuation multiples and competitive fintech landscape pose risks. The stock trades above the $162 consensus target, suggesting near-term consolidation potential before potential upward revisions post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
